# US 10,369,219 B2 · Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,219 B2
- Document ID: US10369219B2
- Status: Granted
- Kind: B2
- Application number: 15/501,271
- Filed: 2015-08-04
- Published: 2017-08-03
- Granted: 2019-08-06
- Earliest claimed: 2014-08-04
- Assignees: Nitto Denko Corporation
- Applicants: Nitto Denko Corporation
- Inventors: Takuya Shishido; Daisuke Asari; Kyohei Matsushita; Mitsuhiko Hori
- Web page: https://patentgrep.com/patent/US10369219B2

## CPC

- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/07: Bacillus
- A61K 39/092: {Streptococcus}
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/20: for DNA viruses
- A61K 2039/52: {Bacterial cells; Fungal cells; Protozoal cells}
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/541: {Mucosal route}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/543: {intranasal}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/575: {humoral response}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- C12N 2710/16734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/12334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/36234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

## Claims

### Claim 1

A method for promoting humoral immunity induction in a subject in need thereof, comprising:
administering to the subject an effective amount of a G protein-coupled receptor (GPCR) ligand that is at least one selected from an antagonist for a Gi-coupled GPCR and an antagonist for a Gq-coupled GPCR.

### Claim 2

A method for promoting humoral immunity induction in a subject in need thereof, comprising:
administering to the subject an effective amount of a pharmaceutical composition comprising:
an antigen for humoral immunity induction; and
a G protein-coupled receptor (GPCR) ligand that is at least one selected from an antagonist for a Gi-coupled GPCR and an antagonist for a Gq-coupled GPCR.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the antagonist is selected from the group consisting of an adrenergic receptor antagonist, a muscarinic receptor antagonist, a dopamine receptor antagonist, a histamine receptor antagonist, a serotonin receptor antagonist, a PAF receptor antagonist, a purine receptor antagonist, a vasopressin receptor antagonist, an opioid receptor antagonist, a leukotriene receptor antagonist, and an angiotensin receptor antagonist.